抑制α-amylase和α-glucosidase 使用白枝叶植物
Pongsathorn Klomsakul1, Pornchanok Chalopagorn2
1Department of Biology, Faculty of Science and Technology, Phranakhon Rajabhat University, Bangkok 10220, Thailand.
Scientifica
|June 24, 2025
概括
一种药用植物Baccaurea ramiflora显示出作为抗糖尿病治疗的潜力. 它的肉,种子和皮的提取物有效地抑制了参与糖尿病的关键酶,提供了天然的治疗可能性.
科学领域:
- 植物化学 植物化学
- 药理学 药理学是指药理学的学科.
- 营养学科学 营养学科学
背景情况:
- 糖尿病是一种日益严重的全球健康问题,需要寻找具有较少副作用的新型治疗方法.
- 像Baccaurea ramiflora这样的药用植物正在越来越多地研究它们的治疗潜力.
研究的目的:
- 为了评估各种Baccaurea ramiflora提取物的抗糖尿病潜力.
- 为了确定B. ramiflora提取物中的和黄含量和酶抑制活性.
主要方法:
- 乙醇提取物是从B. ramiflora的不同部分 (叶子,茎,茎皮,皮,肉和种子) 中制备的.
- 总的和黄酸盐含量被量化.
- 评估了对α-amylase和α-glucosidase酶的抑制活性.
- 气色谱-质谱法 (GC-MS) 用于活性提取物的化学分析.
主要成果:
- 叶子,含有种子的肉和皮的提取物富含;叶子提取物具有最高的黄酸含量.
- 带有种子和皮的肉体显示出对α-氨酶和α-葡萄糖酶的显著抑制活性.
- 所有提取物的酶抑制都依赖于度.
- GC-MS分析确定了活性提取物中的关键化合物,如衍生物和酸盐.
结论:
- 百花树提取物具有显著的抗糖尿病特性,这是由于其和黄酸含量以及酶抑制作用.
- 这种植物有望发展成为营养药,功能性食品和糖尿病管理的治疗剂.
相关概念视频
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
276
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
276
Dipeptidyl Peptidase 4 Inhibitors
271
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
271
Carbohydrate Digestion
117.9K
Carbohydrate digestion and metabolism break down simple and complex carbohydrates from food into saccharides (i.e., sugars) for the body to use as energy. Carbohydrate digestion starts in the mouth during mastication, or chewing. The masticated carbohydrates remain intact in the stomach. Digestion resumes in the duodenum of the small intestine, where pancreatic alpha-amylase and brush border enzymes of the microvilli convert complex carbohydrates to monosaccharides. Finally, the monosaccharides...
117.9K
Glucagon-like Receptor Agonists
435
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
435
Hormones Regulating Blood Glucose
4.1K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
4.1K
Oral Hypoglycemic Agents: Glinides
274
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
274


